Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism

Fedra Najjar, Thomas Owley, Matthew W. Mosconi, Suma Jacob, Kwan Hur, Stephen J. Guter, John A. Sweeney, Robert D. Gibbons, Edwin H. Cook, Jeffrey R. Bishop

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD). Methods: Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment outcomes and drug doses. Results: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genotype groups. Similarly, dosing trajectory was not significantly associated with genotype groups. Conclusions: Previous studies have identified SLC6A4 and HTR2A associations with SSRI response in patients with depression and 5-HTTLPR (SLC6A4) associations with escitalopram response in ASD. We did not observe evidence for similar relationships in this ASD study.

Original languageEnglish (US)
Pages (from-to)467-474
Number of pages8
JournalJournal of Child and Adolescent Psychopharmacology
Volume25
Issue number6
DOIs
StatePublished - Aug 1 2015

Fingerprint

Serotonin Plasma Membrane Transport Proteins
Autistic Disorder
Citalopram
Genotype
Serotonin Uptake Inhibitors
Receptor, Serotonin, 5-HT2A
Depression
Pharmacogenomic Testing
Autism Spectrum Disorder
Pharmaceutical Preparations
Genes
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Najjar, F., Owley, T., Mosconi, M. W., Jacob, S., Hur, K., Guter, S. J., ... Bishop, J. R. (2015). Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism. Journal of Child and Adolescent Psychopharmacology, 25(6), 467-474. https://doi.org/10.1089/cap.2014.0158

Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism. / Najjar, Fedra; Owley, Thomas; Mosconi, Matthew W.; Jacob, Suma; Hur, Kwan; Guter, Stephen J.; Sweeney, John A.; Gibbons, Robert D.; Cook, Edwin H.; Bishop, Jeffrey R.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 25, No. 6, 01.08.2015, p. 467-474.

Research output: Contribution to journalArticle

Najjar, F, Owley, T, Mosconi, MW, Jacob, S, Hur, K, Guter, SJ, Sweeney, JA, Gibbons, RD, Cook, EH & Bishop, JR 2015, 'Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism', Journal of Child and Adolescent Psychopharmacology, vol. 25, no. 6, pp. 467-474. https://doi.org/10.1089/cap.2014.0158
Najjar, Fedra ; Owley, Thomas ; Mosconi, Matthew W. ; Jacob, Suma ; Hur, Kwan ; Guter, Stephen J. ; Sweeney, John A. ; Gibbons, Robert D. ; Cook, Edwin H. ; Bishop, Jeffrey R. / Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism. In: Journal of Child and Adolescent Psychopharmacology. 2015 ; Vol. 25, No. 6. pp. 467-474.
@article{b71a09fdb7f2497d8045279d5762a364,
title = "Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism",
abstract = "Objective: The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD). Methods: Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment outcomes and drug doses. Results: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genotype groups. Similarly, dosing trajectory was not significantly associated with genotype groups. Conclusions: Previous studies have identified SLC6A4 and HTR2A associations with SSRI response in patients with depression and 5-HTTLPR (SLC6A4) associations with escitalopram response in ASD. We did not observe evidence for similar relationships in this ASD study.",
author = "Fedra Najjar and Thomas Owley and Mosconi, {Matthew W.} and Suma Jacob and Kwan Hur and Guter, {Stephen J.} and Sweeney, {John A.} and Gibbons, {Robert D.} and Cook, {Edwin H.} and Bishop, {Jeffrey R.}",
year = "2015",
month = "8",
day = "1",
doi = "10.1089/cap.2014.0158",
language = "English (US)",
volume = "25",
pages = "467--474",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Pharmacogenetic study of serotonin transporter and 5HT2A genotypes in autism

AU - Najjar, Fedra

AU - Owley, Thomas

AU - Mosconi, Matthew W.

AU - Jacob, Suma

AU - Hur, Kwan

AU - Guter, Stephen J.

AU - Sweeney, John A.

AU - Gibbons, Robert D.

AU - Cook, Edwin H.

AU - Bishop, Jeffrey R.

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Objective: The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD). Methods: Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment outcomes and drug doses. Results: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genotype groups. Similarly, dosing trajectory was not significantly associated with genotype groups. Conclusions: Previous studies have identified SLC6A4 and HTR2A associations with SSRI response in patients with depression and 5-HTTLPR (SLC6A4) associations with escitalopram response in ASD. We did not observe evidence for similar relationships in this ASD study.

AB - Objective: The purpose of this study was to determine whether polymorphisms in the serotonin transporter (SLC6A4) and serotonin-2A receptor (HTR2A) genes are associated with response to escitalopram in patients with autism spectrum disorder (ASD). Methods: Forty-four participants with ASD were enrolled in a 6 week, forced titration, open label examination of the selective serotonin reuptake inhibitor (SSRI) escitalopram. Doses increased at weekly intervals starting at 2.5mg daily with a maximum possible dose of 20mg daily achieved by the end of the study. If adverse events were experienced, participants subsequently received the previously tolerated dose for the duration of study. SLC6A4 (5-HTTLPR) and HTR2A (rs7997012) genotype groups were assessed in relation to treatment outcomes and drug doses. Results: Insistence on sameness and irritability symptoms significantly improved over the course of the 6 week treatment period (p<0.0001) in this open-label trial. There were no significant differences observed in the rate of symptom improvement over time across genotype groups. Similarly, dosing trajectory was not significantly associated with genotype groups. Conclusions: Previous studies have identified SLC6A4 and HTR2A associations with SSRI response in patients with depression and 5-HTTLPR (SLC6A4) associations with escitalopram response in ASD. We did not observe evidence for similar relationships in this ASD study.

UR - http://www.scopus.com/inward/record.url?scp=84939201465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939201465&partnerID=8YFLogxK

U2 - 10.1089/cap.2014.0158

DO - 10.1089/cap.2014.0158

M3 - Article

C2 - 26262902

AN - SCOPUS:84939201465

VL - 25

SP - 467

EP - 474

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 6

ER -